<DOC>
	<DOCNO>NCT00165451</DOCNO>
	<brief_summary>This study use combination four oral drug ( thalidomide , cyclophosphamide , etoposide celecoxib ) treat patient relapse progressive cancer . These drug expect target blood vessel supply tumor need grow .</brief_summary>
	<brief_title>A Trial Thalidomide , Celecoxib , Etoposide Cyclophosphamide Patients With Relapsed Progressive Cancer</brief_title>
	<detailed_description>- Thalidomide give orally every evening daily dose escalate patient reach dose comfortable give continuously one year . - Celecoxib give orally twice day escalate tolerate one year . - Etoposide give orally day 21 consecutive day . This medication alternate oral cyclophosphamide continue one year . - Cyclophosphamide give orally day 21 consecutive day state alternate etoposide one year . - During treatment , blood test perform every three week except first 3 week cycle test perform every 2 week . Appropriate image study perform every 9 week . - The duration treatment one year unless side effect harmful tumor grows . Treatment may continue past one year drug well tolerate disease progression occur .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Patients relapse progressive poor prognosis tumor curative therapy exists . Histologic confirmation disease diagnosis relapse . Brain stem glioma patient progress radiation therapy require histologic confirmation . Duration symptoms time diagnosis must less 3 month consist cranial nerve deficit and/or ataxia and/or long tract sign . Prior radiation therapy and/or chemotherapy permit . Karnofsky Performance Status &gt; 50 . For infant , Lansky play scale &gt; 50 % substitute . Life expectancy &gt; 2 month . No active uncontrolled cardiac , hepatic , renal , psychiatric disease define â‰¥ grade 3 base common toxicity criterion . No known allergy sulfonamides Adequate renal function : Serum Creatinine &lt; 1.5 mg/dl creatinine clearance GFR &gt; 70 ml/min . Adequate hepatic function : Total Bilirubin &lt; 1.5 mg/dl ; SGOT , SGPT , Alk Phos &lt; 3x normal . ( SGOT &lt; 4x normal patient Zantac ) . Adequate bone marrow reserve : Hgb &gt; 9.0 g/dl , Platelets &gt; 75,000/mm3 ( transfusion independent ) , WBC &gt; 2000/mm3 ANC &gt; 1000/mm3 . Patients receive steroid and/or antiseizure medication eligible study . Patients must pregnant nursing , patient child bear age ( male female ) must willing practice birth control 2 month treatment thalidomide . If patient unable use oral contraceptive medical reason , 2 different barrier method may use approve treat physician . No concurrent use investigational agent . Patients receive 2 month oral therapy agent use study ineligible . Standard administration IV etoposide cyclophosphamide , usually administer 3week cycle permit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Relapsed tumor</keyword>
	<keyword>Progressive Poor Prognosis Tumors</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>